Cookies help us deliver our services. By using our services, you agree to our use of cookies.
Learn more
OK
Skip to main content (Press Enter).
Sign In
Skip auxiliary navigation (Press Enter).
Contact Us
Skip main navigation (Press Enter).
Toggle navigation
Search Options
About
What is the AMS
AMS International Scientific Committee
AMS North America Scientific Committee
AMS Educational Executive Committee
AMS Ambassadors
Certifications and Educational Credits
Upcoming Events
Videos & Webinars
International Events
Become a Speaker
Videos On Demand
Education 365
Preview AMS TV
Features
AMS Features
News & Publications
AMS Bookstore
Blogs
Industry
Industry Partners
Become a Sponsor
Features
Blogs
Blog Viewer
Blogs
COVID-19 in 3 patients treated with immune checkpoint inhibitors for advanced melanoma
By
- AMS
posted
Oct 23, 2020 08:37 AM
0
Recommend
.
0 comments
0 views
Permalink
Related Content
Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses
- AMS
Added Mar 23, 2021
Blog Entry
A time series analysis of immune checkpoint inhibitor use in the United States Medicare population: 2014–2019
- AMS
Added Aug 11, 2021
Blog Entry
MINERVA RESEARCH LABS ON COVID 19 TESTS
- AMS
Added Apr 30, 2020
Blog Entry
The impact of COVID-19 pandemic in a cohort of Italian psoriatic patients treated with biological therapies
- AMS
Added Aug 04, 2020
Blog Entry
Long-term vemurafenib therapy in advanced melanoma patients: cutaneous toxicity and prognostic implications
- AMS
Added Sep 10, 2020
Blog Entry
© 2022 AMS, Aesthetic Multispecialty Society. All Rights Reserved.
Powered by Higher Logic